Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patient-Reported Outcomes Are Key To Understanding Success of Bundled Payments – NPC’s Dubois

This article was originally published in The Pink Sheet Daily

Executive Summary

Experience with the end-stage renal disease prospective payment system reveals a valuable lesson – that patient-related quality metrics are needed to fully assess the impact the system has on the patient, something that will be valuable when bundling is considered for treatments where drug costs are significant.

Advertisement

Related Content

GAO Tracks Decline In ESA Use Following Regulatory Changes
Delaying Inclusion Of Oral-Only ESRD Drugs In Bundled Payment Gives Short-Term Reprieve To Genzyme, Amgen
ESRD Bundling Debate Shifts To Congress With Receipt Of CMS Report

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075816

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel